FDA's review of Coherus BioSciences Inc.'s Neulasta (pegfilgrastim) biosimilar application could shed light on the data sponsors must submit to gain approval of their versions of the granulocyte-colony stimulating factor, particularly whether they must conduct studies in a patient population.
Apotex Inc. submitted a citizen petition to FDA in April asking the agency to require sponsors referencing Amgen...